Risvutatug rezetecan

DB23560InvestigationalProtein Based Therapies

Risvutatug rezetecan (GSK5764227) is a novel investigational B7-H3-targeted antibody-drug conjugate. It is under investigation in clinical trial NCT06885034 (A Study to Test the Safety and Effectiveness of GSK5764227, Alone or...

Mechanism: Pharmacologically active on CD276 antigen
Curator reviewed
Code names: GSK5764227 · HS-20093

Resolves to

Compound

UNII7T9A6CKG67

Targets

Q5ZPR3CD276

What you can answer from here — as of September 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

33Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Risvutatug rezetecan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account